The Center for Drug Evaluation of China’s National Medical Products Administration granted Breakthrough Therapy designation to olverembatinib, combination with low-intensity chemotherapy, for the first-line treatment of newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
A recent population-based study indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying. The findings are published by Wiley online in CANCER.
